SciELO - Scientific Electronic Library Online

 
vol.35 issue2Differences in working memory performance between men and women aged 49 and over in Medellin, AntioquiaTreatment of status epilepticus, an expert consensus report. Colombian Neurology Association - Epilepsy Committee author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Acta Neurológica Colombiana

Print version ISSN 0120-8748

Abstract

CASALLAS VANEGAS, Adriana; ZULUAGA RODAS, Maria Isabel  and  REYES GUERRERO, Marco Aurelio. Clinically isolated syndrome: approach to the first demyelinating event. Acta Neurol Colomb. [online]. 2019, vol.35, n.2, pp.64-73. ISSN 0120-8748.  http://dx.doi.org/10.22379/24224022236.

Clinically Isolated Syndrome (CIS), denotes the first neurological symptom suggestive of Multiple Sclerosis (MS), at least 24 hours in duration; In the absence of fever, infectious processes and encephalopathy. It is characterized by its frequent presentation in young adults and affects the optic nerve, brainstem or spinal cord. The early stratification of CIS is essential because with clinical, radiological and biological predictors, the risk of conversion to MS can be established. The use of Disease Modifying Therapies (DMT) in CIS has been shown to delay the conversion of CIS to Multiple Sclerosis by 44 to 50 %%. However, not all patients with CIS will evolve to MS, so the study of several prognostic markers will allow to recognize the ideal scenario where patients benefit from the early onset of DMT.

Keywords : Demyelinating Diseases; Oligoclonal bands; Multiple Sclerosis; Magnetic Resonance; Cerebroespinal Fluid; Drug therapy (MeSH).

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )